Small-molecule MMRi36 induces apoptosis in p53-mutant lymphomas by targeting MDM2/MDM4/XIAP for degradation

Small-molecule MMRi36 induces apoptosis in p53-mutant lymphomas by targeting MDM2/MDM4/XIAP for degradation

Rituximab combined with systemic chemotherapy significantly improves the rate of complete response in B-cell lymphomas. However, acquired rituximab resistance develops in most patients leading to relapse. The mechanisms underlying rituximab resistance are not well-understood. MDM2 and MDM4 proteins...

Full description

Saved in:
Bibliographic Details
Main Authors: Rati Lama, Wenjie Wu, Cory K. Mavis, Federico M. Ruiz, Javier Querol-García, Diana Martin, Sherry R. Chemler, Dhyan Chandra, David W. Goodrich, Francisco J. Hernandez-Ilizaliturri, Inés G. Muñoz, Xinjiang Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
MMRi36
MDM2
MDM4
XIAP
mutant p53
Rituximab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1462231/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items